Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: Current status and evolving concepts

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 15, Issue 4, 2002, Pages 757-769

  Ottmann, Oliver G ^a   Wassmann, Barbara ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Acute lymphoblastic leukaemia; BCR ABL; Kinase inhibitor; Minimal residual disease; Philadelphia chromosome; Stem cell transplantation; STI571; Targeted therapy

Indexed keywords

2 AMINOPYRIDINE DERIVATIVE; ALPHA INTERFERON; ANTIFUNGAL AGENT; ANTILEUKEMIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CYCLOSPORIN A; CYTOCHROME P450; CYTOCHROME P450 3A4; ENZYME INHIBITOR; IMATINIB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRROLE; SIMVASTATIN; ANTIINFECTIVE AGENT; BCR ABL PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; OROSOMUCOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; BLOOD TOXICITY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CROSS REACTION; DIARRHEA; DRUG ABSORPTION; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FACE EDEMA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE RESPONSE; LONG TERM CARE; MINIMAL RESIDUAL DISEASE; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; RASH; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; ALLOGENEIC STEM CELL TRANSPLANTATION; BLEEDING; CANCER RELAPSE; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM DISEASE; CHROMOSOME TRANSLOCATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG METABOLISM; DRUG POTENTIATION; ENZYME ACTIVITY; INFECTION; LEUKEMOGENESIS; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; SKULL IRRADIATION;

EID: 0036950191     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2002.0233     Document Type: Review

References (51)

1. Gleißner B, Gökbuget N, Bartram C et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002; 99: 1536-1543.
2. Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Advances in the treatment of adult acute lymphocytic leukemia. Hematology and Oncology Clinics of North America 2001; 15: 21-36.
3. Faderl S, Kantarjian HM, Thomas DA et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leukemia and Lymphoma 2000; 36: 263-273.
4. Chan LC, Karhi KK, Rayter SI et al. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia. Nature 1987; 325: 635-637.
5. de Klein A, Hagemeijer A, Bartram CR et al. Bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia. Blood 1986; 68: 1369-1375.
6. Heisterkamp N, Jenkins R, Thibodeau S et al. The bcr gene in Philadelphia chromosome positive acute lymphoblastic leukemia. Blood 1989; 73: 1307-1311.
7. Clark SS, McLaughlin J, Crist WM et al. Unique forms of the abl tyrosine kinase distinguish Phl-positive CML from Phl-positive ALL. Science 1987; 235: 85-88.
8. van Dongen JJ, Macintyre EA, Gabert JA et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-I Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
9. Secker-Walker LM, Craig JM, Hawkins JM et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 1991; 5: 196-199.
10. Sawyers CL. Signal transduction pathways involved in BCR-ABL transformation. Baillière's Clinical Haematology 1997; 10: 223-231.
11. Sausville EA. A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges. Journal of the National Cancer Institute 1999; 91: 102-103.
12. Buchdunger E, Zimmermann J, Mett H et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Research 1996; 56: 100-104.
13. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-Kit and platelet-derived growth factor receptors (in process citation). Journal of Pharmacology and Experimental Therapy 2000; 295: 139-145.
14. Druker BJ, Tamura S, Buchdunger E et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine 1996; 2: 561-566.
15. Beran M, Cao X, Estrov Z et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clinical Cancer Research 1998; 4: 1661-1672.
16. Deininger MW, Goldman JM, Lydon N & Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691-3698.
17. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New England Journal of Medicine 2001; 344: 1038-1042.
18. Ottmann OG, Druker BJ, Sawyers CL et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002; 100: 1965-1971.
19. Wassmann B, Pfeifer H, Scheuring U et al. Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia 2002; 16: 2358-2365.
20. Cornelissen JJ, Carston M, Kollman C et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood 2001; 97: 1572-1577.
21. Ottmann OG, Wassmann B, Pfeifer H et al. Activity of the ABL tyrosine kinase inhibitor Glivec (STI571) in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) relapsing after allogeneic stem cell transplantation (abstract). Blood 2001; 98: 589a-590a.
22. Gökbuget N, Hoelzer D, Arnold R et al. Treatment of Adult ALL according to protocols of the German Multicentre Study Group for Adult ALL (GMALL). Hematology and Oncology Clinics of North America 2000; 14: 1307-1325.
23. Pochedly C. Prevention of meningeal leukemia. Review of 20 years of research and current recommendations. Hematology and Oncology Clinics of North America 1990; 4: 951-969.
24. Saikia TK, Dhabhar B, Iyer RS et al. High incidence of meningeal leukemia in lymphoid blast crisis of chronic myelogenous leukemia. American Journal of Hematology 1993; 43: 10-13.
25. Stark B, Sharon R, Rechavi G et al. Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia: the Israel National Study report. Cancer 2000; 88: 205-216.
26. Gökbuget N & Hoelzer D. Meningeosis leukaemica in adult acute lymphoblastic leukaemia. Journal of Neurooncology 1998; 38: 167-180.
27. Petzer AL, Gunsilius E, Hayes M et al. Low concentrations of STI571 in the cerebrospinal fluid: a case report. British Journal of Haematology 2002; 117: 623-625.
28. Leis JF, Stepan DE, Curtin PT et al. Low penetration of imatinib (STI571) into the CSF indicates the need for standard CNS prophylaxis in patients with CML lymphoid blast crisis and Philadelphia chromosome positive ALL (abstract). Blood 2001; 98: 140a.
29. Singhal S, Powles R, Treleaven J et al. Central nervous system relapse after bone marrow transplantation for acute leukemia in first remission. Bone Marrow Transplantion 1996; 17: 637-641.
30. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine 2001; 344: 1031-1037.
31. Sawyers CL, Hochhaus A, Silver RT et al. Glivec™ (imatinib mesylate) induces haematological and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530-3539.
32. Talpaz M, Silver RT, Druker BJ et al. Imatinib induces durable haematological and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
33. +ALL): Extended Follow-Up and Analysis of Prognostic Factors (abstract). Blood 2002; 100: 87a.
34. Mahon FX, Deininger MW, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000; 96: 1070-1079.
35. Shannon K. Resistance in the land of molecular cancer therapeutics. Cancer Cell 2002; 2: 99.
36. Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukaemic cells to the abl inhibitor STI571. Journal of the National Cancer Institute 2000; 92: 1641-1650.
37. le Coutre P, Tassi E, Varella-Garcia M et al. Induction of resistance to the Abelson inhibitor STI571 in human leukaemic cells through gene amplification. Blood 2000; 95: 1758-1766.
38. Weisberg E & Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 2000; 95: 3498-3505.
39. Hofmann WK, Jones LC, Lemp NA et al. Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 2002; 99: 1860-1862.
40. von Bubnoff N, Schneller F, Peschel C & Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 2002; 359: 487-491.
41. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by bcr-abl gene mutation or amplification. Science 2001; 293: 876-880.
42. Hochhaus A, Kreil S, Corbin AS et al. Roots of clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163a.
43. Barthe C, Cony-Makhoul P, Melo JV et al. Roots of Clinical resistance to STI-571 cancer therapy. Science 2001; 293: 2163a.
44. +ALL) with the Abl-tyrosine kinase inhibitor STI571 (Glivec). Blood 2003; 101: 85-90.
45. O'Brien SG, Peng B, Dutreix C et al. A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate, in patients with chronic myeloid leukemia (abstract). Blood 2002; 98: 593.
46. Kano Y, Akutsu M, Tsunoda S et al. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 2001; 917: 1999-2007.
47. Thiesing JT, Ohno-Jones S, Kolibaba KS & Druker BJ. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195-3199.
48. Topaly J, Zeller WJ & Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342-347.
49. Thomas DA, Cortes J, Giles FJ et al. Combination of Hyper-CVAD with Imatinib Mesylate (STI571) for Philadelphia (Ph)-positive adult acute lymphoblastic leukemia (ALL) or chronic myelogenous leukemia in lymphoid blast phase (CML-LBP) (abstract). Blood 2001; 98: 802a.
50. Hoover RR, Mahon FX, Melo JV & Daley GQ. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood 2002; 100: 1068-1071.
51. Klejman A, Rushen L, Morrione A et al. Phosphatidylinositol-3 kinase inhibitors enhance the antileukemia effect of STI571. Oncogene 2002; 21: 5868-5876.